公开(公告)号：US20240199548A1

公开(公告)日：2024-06-20

申请号：US18283834

申请日：2022-03-25

申请人： Jacobio Pharmaceuticals Co., Ltd.

发明人： Yang YE ,  Xiuwei LI ,  Guiqun YANG ,  Fashun YAN ,  Yanping WANG ,  Wei LONG

IPC分类号： C07D209/44 ,  A61K31/4035 ,  A61K31/437 ,  A61K45/06 ,  C07D471/04

CPC分类号： C07D209/44 ,  A61K31/4035 ,  A61K31/437 ,  A61K45/06 ,  C07D471/04

摘要： Compounds of general Formula S-1, S-2, S-3 and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, compositions, and uses of such compounds.

公开(公告)号：US20240166608A1

公开(公告)日：2024-05-23

申请号：US18529689

申请日：2023-12-05

申请人： Insilico Medicine IP Limited

发明人： Xiao DING ,  Jinxin LIU ,  Feng REN ,  Jianfei WAN ,  Wei ZHU

IPC分类号： C07D231/56 ,  A61P35/00 ,  C07D209/44 ,  C07D215/14 ,  C07D401/04 ,  C07D403/08 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D231/56 ,  A61P35/00 ,  C07D209/44 ,  C07D215/14 ,  C07D401/04 ,  C07D403/08 ,  C07D471/04 ,  C07D487/04

摘要： The disclosure provides for compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical compositions.

公开(公告)号：US20240083883A1

公开(公告)日：2024-03-14

申请号：US18270624

申请日：2021-12-31

申请人： Sarissa Inc.

发明人： Mark David VINCENT ,  Peter John Ferguson ,  Donald James Koropatnick

IPC分类号： C07D403/14 ,  A61K31/138 ,  A61K31/4166 ,  A61K31/44 ,  A61K31/506 ,  A61K31/517 ,  A61P35/00 ,  C07D209/44 ,  C07D401/10 ,  C07D471/04

CPC分类号： C07D403/14 ,  A61K31/138 ,  A61K31/4166 ,  A61K31/44 ,  A61K31/506 ,  A61K31/517 ,  A61P35/00 ,  C07D209/44 ,  C07D401/10 ,  C07D471/04

摘要： The present invention provides RAD51 inhibitors having the structural formula (I): or a pharmaceutically acceptable salt or solvate thereof. Also provided are methods of treating or preventing cancer comprising administration of the compounds of the present invention, as well as uses of the compounds to induce a synergistic effect with known chemotherapeutic.

公开(公告)号：US11760764B2

公开(公告)日：2023-09-19

申请号：US17303089

申请日：2021-05-19

申请人： Aligos Therapeutics, Inc.

发明人： Tongfei Wu ,  Pierre Jean-Marie Bernard Raboisson ,  Antitsa Dimitrova Stoycheva ,  Francois Gonzalvez ,  Jerome Deval ,  Cheng Liu

IPC分类号： C07D519/00 ,  C07C229/16 ,  C07C215/14 ,  C07D233/36 ,  C07D207/267 ,  C07D295/135 ,  C07D217/02 ,  C07D209/44 ,  C07C211/42 ,  C07D205/12 ,  C07D491/107 ,  C07D217/04 ,  C07D401/14 ,  C07D471/04 ,  C07C233/36

CPC分类号： C07D519/00 ,  C07C211/42 ,  C07C215/14 ,  C07C229/16 ,  C07C233/36 ,  C07D205/12 ,  C07D207/267 ,  C07D209/44 ,  C07D217/02 ,  C07D217/04 ,  C07D295/135 ,  C07D401/14 ,  C07D471/04 ,  C07D491/107 ,  C07C2602/08

摘要： The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

公开(公告)号：US20230143250A1

公开(公告)日：2023-05-11

申请号：US17891436

申请日：2022-08-19

申请人： Enanta Pharmaceuticals, Inc.

发明人： Guoqiang Wang ,  Jun Ma ,  Brett Granger ,  Jiang Long ,  Bin Wang ,  Sourav Ghorai ,  Jing He ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Yat Sun Or

IPC分类号： C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

CPC分类号： C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

摘要： The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US20220315567A1

公开(公告)日：2022-10-06

申请号：US17520350

申请日：2021-11-05

申请人： Mebias Discovery, Inc.

发明人： Brett A. Tounge ,  Shariff Bayoumy ,  Lawrence C. Kuo ,  Scott Dax

IPC分类号： C07D409/12 ,  C07D405/12 ,  C07D209/44 ,  C07C275/14 ,  C07C275/06 ,  A61P29/00 ,  C07C275/26 ,  C07C273/18 ,  C07D215/08 ,  C07D333/20 ,  C07D215/18 ,  C07C275/28 ,  C07D207/09 ,  C07D215/14 ,  C07D333/22

摘要： The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

公开(公告)号：US20220281815A1

公开(公告)日：2022-09-08

申请号：US17733736

申请日：2022-04-29

申请人： JUBILANT BIOSYS LIMITED

发明人： Sridharan RAJAGOPAL ,  Mahanandeesha S. HALLUR ,  Purushottam DEWANG ,  Kannan MURUGAN ,  Durga Prasanna KUMAR C.H. ,  Pravin IYER ,  Chandrika MULAKALA ,  Dhanalakshmi SIVANANDHAN ,  Sreekala NAIR ,  Mohd ZAINUDDIN ,  Subramanyam Janardhan TANTRY ,  Chandru GAJENDRAN ,  Sriram RAJAGOPAL

IPC分类号： C07D205/12 ,  A61P35/00 ,  C07C235/56 ,  C07C237/20 ,  C07C259/08 ,  C07D205/04 ,  C07D211/26 ,  C07D217/18 ,  C07D231/12 ,  C07D233/64 ,  C07D239/26 ,  C07D249/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D209/44

摘要： The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

公开(公告)号：US20220055990A1

公开(公告)日：2022-02-24

申请号：US17299602

申请日：2019-12-05

申请人： DAIKIN INDUSTRIES, LTD.

发明人： Naoyuki HOSHIYA ,  Motoshi MATSUI ,  Yosuke KISHIKAWA

IPC分类号： C07D211/76 ,  C07D207/27 ,  C07D209/44 ,  C07D263/22 ,  C07C231/12 ,  B01J23/44

摘要： An object of this disclosure provides a novel method for producing a fluorovinyl amide compound and the like. The object is achieved by a method for producing a compound represented by formula (1): wherein Rf is —F or fluoroalkyl, Ra1 is —H or an organic group, and Ra2 is —H or an organic group, or (i) Ra1 and Ra2, (ii) Ra1 and Rf, or (iii) Rf and Ra2, may be linked to each other, Rb1 is —H or an organic group, and Rb2 is —H or an organic group, or Rb1 and Rb2 may be linked together with their adjacent atoms to form a nitrogen-containing ring optionally having one or more substituents, the method comprising step A of reacting a compound represented by formula (2): wherein Rx is a leaving group, with a compound represented by formula (3) or a salt thereof: in the presence of a transition metal catalyst.

公开(公告)号：US11242317B2

公开(公告)日：2022-02-08

申请号：US16519590

申请日：2019-07-23

申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

发明人： Troy E. Messick ,  Garry R. Smith ,  Allen B. Reitz ,  Paul M. Lieberman ,  Mark E. McDonnell ,  Yan Zhang ,  Venkata Velvadapu

IPC分类号： A61K31/405 ,  A61K31/41 ,  A61K31/42 ,  A61K31/415 ,  A61K31/40 ,  C07D515/02 ,  C07D209/44 ,  C07D295/04 ,  C07D261/06 ,  C07D233/02 ,  C07D233/00 ,  C07D207/327 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/192 ,  A61K31/44 ,  C07C229/56 ,  C07C255/54 ,  C07C255/55 ,  C07C211/27 ,  C07C217/84 ,  C07C233/11 ,  C07C233/64 ,  C07C233/65 ,  C07C235/58 ,  C07C311/08 ,  C07C311/16 ,  C07C311/17 ,  C07C317/14 ,  C07D235/06 ,  C07D403/10 ,  C07D239/26 ,  C07D409/10 ,  C07D417/10 ,  C07D471/04 ,  C07D487/04 ,  C07D209/08 ,  C07D295/155 ,  C07D213/55 ,  C07C53/18 ,  C07C63/66 ,  C07C65/19 ,  C07C65/28 ,  C07C229/64 ,  C07C317/44 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D211/70 ,  C07D213/64 ,  C07D213/74 ,  C07D215/14 ,  C07D231/12 ,  C07D249/06 ,  C07D277/30 ,  C07D307/79 ,  C07D333/54 ,  C07D401/04 ,  C07D401/10

摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

公开(公告)号：US11198685B2

公开(公告)日：2021-12-14

申请号：US16876222

申请日：2020-05-18

申请人： Mebias Discovery, Inc.

发明人： Brett A. Tounge ,  Shariff Bayoumy ,  Lawrence C. Kuo ,  Scott Dax

IPC分类号： C07D409/12 ,  C07D405/12 ,  C07D209/44 ,  C07C275/14 ,  C07C275/06 ,  A61P29/00 ,  C07C275/26 ,  C07C273/18 ,  C07D215/08 ,  C07D333/20 ,  C07D215/18 ,  C07C275/28 ,  C07D207/09 ,  C07D215/14 ,  C07D333/22

摘要： The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.